Clinical Trial Update: PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis [Phase 2]

View source ↗

Summary

Phase 2 PaTH study evaluating parathyroid hormone (teriparatide) and alendronate for osteoporosis has completed, with results reported in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• FOSAMAX (ALENDRONATE SODIUM)
• Forteo (teriparatide)

Snippet

Sponsor: Dennis Black | Conditions: Osteoporosis | Phase 2 | Status: COMPLETED